Melanoma Immunotherapy: What's Next for Patients? with Antoni Ribas

Melanoma Immunotherapy: What's Next for Patients? with Antoni RibasПодробнее

Dr. Antoni Ribas on the Search for Immunotherapy Biomarkers in MelanomaПодробнее

Sequencing Agents for the Treatment of Patients With MelanomaПодробнее

Dr. Antoni Ribas on the Efficacy of Lambrolizumab in Advanced MelanomaПодробнее

Dr. Antoni Ribas Discusses the Giants of Cancer Care ProgramПодробнее

Dr. Ribas on Combination Immunotherapy and Radiation in MelanomaПодробнее

Dr. Antoni Ribas on Combining Vemurafenib and Ipilimumab for Metastatic MelanomaПодробнее

Dr. Ribas on the Excitement Surrounding Immunotherapies for MelanomaПодробнее

Dr. Antoni Ribas: 2015 Giants of Cancer Care WinnerПодробнее

Dr. Ribas on the Efficacy of Ipilimumab in MelanomaПодробнее

Case I: Newly Diagnosed BRAF–Wild Type Advanced MelanomaПодробнее

The Changing Landscape of Melanoma TherapiesПодробнее

Melanoma dedifferentiation as an escape mechanism for immunotherapy and ACTПодробнее

Dr. Ribas on the Outlook for BRAF Inhibitors in MelanomaПодробнее

Pioneering melanoma treatment – Georgina Long & Richard Scolyer | AOTY | ABCПодробнее

Immunotherapy in Melanoma: Managing ToxicitiesПодробнее

Dr. Antoni Ribas on Anti-PD-1 Agent Lambrolizumab in Advanced MelanomaПодробнее

Dr. Ribas Discusses the Developmental Process of MK-3475 in MelanomaПодробнее

Dr. James Allison #cancerresearcher #melanoma #oncology #biopharma #youtubeshorts #viral #scientistПодробнее

Dr. Ribas on Triplet Regimens in MelanomaПодробнее